<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619423</url>
  </required_header>
  <id_info>
    <org_study_id>PP095, (PLIANT)</org_study_id>
    <secondary_id>2012-001367-76</secondary_id>
    <nct_id>NCT01619423</nct_id>
  </id_info>
  <brief_title>A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>PLIANT</acronym>
  <official_title>A Double Blinded Randomised Three Armed Phase II Trial of PledOx in Two Different Doses in Combination With FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Advanced Metastatic Colorectal (Stage IV) Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PledPharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharma Consulting Group AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PledPharma AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is designed to determine whether pre-treatment with PledOx lowers the
      frequency and severity of side effects from FOLFOX6 administration in patients with
      metastatic colorectal cancer.

      The efficacy of two different doses of PledOx will be assessed when added to FOLFOX6
      chemotherapy as first line treatment of metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Globally, nearly 800 000 colorectal cancers are believed to occur annually. Approximately
      about half of the patients with colorectal cancer develop metastatic disease. These patients
      are often offered chemotherapy with the FOLFOX6 regimen (FOL = FOLic acid; F = Fluorouracil
      (5-FU); OX = OXaliplatin) The use of FOLFOX6 is, however, hampered by a high incidence and
      severity of adverse reactions.

      In the current trial patients will receive the antioxidant agent PledOx in one of two
      different doses, or placebo, in the first 8 cycles of FOLFOX6 treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of neuropathy grade 2 or higher (according to the Sanofi-NCI criteria for oxaliplatin related paraesthesiae/dysaesthesiae)</measure>
    <time_frame>Every second week, in 16 weeks and thereafter every 12th week for up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Febrile neutropenia</measure>
    <time_frame>Every second week, in 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT or MRI of thorax, abdomen and pelvis</measure>
    <time_frame>From baseline until progression or up to 16 months, whichever comes first</time_frame>
    <description>Response Rate (RR) and Progression Free Survival (PFS)as assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of positive cold allodynia test assessed by subjects</measure>
    <time_frame>Every second week, in 16 weeks</time_frame>
    <description>This assessment is novel and will be measured on 0-10 numerical rating scales where 0 = no pain and 10 = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxaliplatin-associated sensory neuropathy</measure>
    <time_frame>Every second week, in 16 weeks and thereafter every 12th week for up to 12 months.</time_frame>
    <description>Assessed by a patient reported outcome scale (Leonard et al.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Neutrophil count from both baseline and in between readings</measure>
    <time_frame>Every second week, in 16 weeks</time_frame>
    <description>As defined by neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral mucositis</measure>
    <time_frame>Every second week, in 16 weeks and thereafter every 12th week for up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in white blood cell count both from baseline and in between readings</measure>
    <time_frame>Every second week, in 16 weeks and thereafter every 12th week up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet count from both baseline and in between readings</measure>
    <time_frame>Every second week, in 16 weeks adn thereafter every 12th week for up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in haemoglobin from both baseline and in between readings</measure>
    <time_frame>Every second week, in 16 weeks and thereafter every 12th week for up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FOLFOX6 dose frequency and intensity</measure>
    <time_frame>Every second week for up to 16 weeks</time_frame>
    <description>As compared to standard treatment guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>from baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) from baseline</measure>
    <time_frame>Every second week, in 16 weeks and thereafter every 12th week for up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration half-life of of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)</measure>
    <time_frame>From time 0 to last observed concentration</time_frame>
    <description>Dose Escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax) and the corresponding time (Tmax) of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)</measure>
    <time_frame>From time 0 to last observed concentration</time_frame>
    <description>Dose Escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)</measure>
    <time_frame>From time 0 to last observed concentration</time_frame>
    <description>Dose Escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration half-life of of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)</measure>
    <time_frame>From time 0 to last observed concentration</time_frame>
    <description>Randomization phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax) and the corresponding time (Tmax) of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)</measure>
    <time_frame>From time 0 to last observed concentration</time_frame>
    <description>Randomization phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)</measure>
    <time_frame>From time 0 to last observed concentration</time_frame>
    <description>Randomization phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>at appropriate timepoints during the 30 minutes following PledOx administration at the every cycle</time_frame>
    <description>Dose Escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>at appropriate timepoints during the 30 minutes following PledOx administration at the first cycle only</time_frame>
    <description>Randomization phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manganese level in whole blood</measure>
    <time_frame>Change from baseline at 16 weeks or end-of-treatment, whatever comes first</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Advanced Metastatic (Stage IV) Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX6 + PledOx 2 µmol/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX6 + PledOx 5 µmol/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX6 + 0,9% NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PledOx (2 µmol/kg)</intervention_name>
    <description>PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.</description>
    <arm_group_label>FOLFOX6 + PledOx 2 µmol/kg</arm_group_label>
    <other_name>Calmangafodipir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PledOx (5 µmol/kg)</intervention_name>
    <description>PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles</description>
    <arm_group_label>FOLFOX6 + PledOx 5 µmol/kg</arm_group_label>
    <other_name>Calmangafodipir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0,9% NaCl)</intervention_name>
    <description>Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.</description>
    <arm_group_label>FOLFOX6 + 0,9% NaCl</arm_group_label>
    <other_name>Sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced metastatic colorectal (stage IV) cancer verified by biopsy

          -  Patients may have received up to three previous treatment lines of chemotherapy, which
             may include fluoropyrimidine, irinotecan and targeted therapies. The last dose of
             antitumor drug must be given at least 4 weeks prior to inclusion and all toxicity
             (except alopecia and fatigue) resolved. Patients may also be chemotherapy-naïve, have
             received prior adjuvant treatment but no previous treatment with oxaliplatin

          -  CT-scan or MRI of thorax, abdomen and pelvis; within ≤4 weeks before start of
             chemotherapy

          -  Evaluable disease and one measurable site of disease according to RECIST 1.1 criteria
             (at least 10mm for CT-scan or MRI)

          -  Neurological examination with no significant pathological findings

          -  ≥18 years

          -  WHO performance status 0≤2 and Life expectancy ≥ 3 months

          -  Adequate haematological function, Hb ≥ 100 g/L, ANC ≥ 1.5 x 109/L, platelets ≥ 100 x
             109/L

          -  Adequate renal and hepatic functions: creatinine clearance &gt;50 cc/min, total bilirubin
             ≤ 1.5 times ULN, ASAT and ALAT ≤ 3 times ULN (ASAT and ALAT ≤ 5 times ULN in case of
             liver metastases)

          -  INR ≤1.5 times ULN, unless receiving therapeutic anticoagulation

          -  Negative pregnancy test for females of child-producing potential

          -  Written informed consent given

        Exclusion Criteria:

          -  Tumours other than colorectal adenocarcinomas (within the previous 5 years) except for
             curatively treated non melanoma skin cancer or in situ carcinoma of the cervix

          -  Evidence of central nervous system metastases

          -  Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or
             ulcerative colitis

          -  History of cardiac disease with a New York Heart Association (NYHA) Class II or
             greater congestive heart failure, myocardial infarction or unstable angina in the past
             six (6) months prior to Day 1 of treatment and serious arrhythmias requiring
             medication for treatment

          -  Prolonged QTC interval &gt;450 msec

          -  Known history of stroke or cerebrovascular accident in the past six (6) months

          -  Severe diarrhoea

          -  Chronic infection or uncontrolled serious illness causing immunodeficiency

          -  Any uncontrolled serious illness or medical condition

          -  Received mangafodipir at any time

          -  Welders, mine workers or other workers in occupations (current or past) where high
             manganese exposure is likely

          -  Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's etc.)
             or neuromuscular disorder (Multiple sclerosis, Amyotrophic lateral sclerosis, Polio,
             hereditary neuromuscular disease)

          -  Major psychiatric disorder (major depression, psychosis)

          -  Participation in another clinical study with an investigational medicinal product
             within 1 month prior to inclusion.

          -  Blood manganese concentration values &gt;18.3 μg/L at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bengtson</last_name>
    <role>Study Director</role>
    <affiliation>PledPharma AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology &amp; Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Medical Associates Oncology and Hematology</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute @ Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center-Plovdiv EOOD, Department of Medical Oncology and oncology diseases in gastroenterology</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center-Shumen EOOD, Department of Medical Oncology</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Serdika&quot; EOOD, Department of Medical Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Tzaritza Joanna-ISUL&quot; EAD, Clinic of Medical Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATO EAD, Sofia, Clinic of Chemotherapy</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital, Dept of Oncology, Clinical Research Unit</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Klinisk Forsknings Enhed, Onkologisk Afdelig R</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Clinic Medina</name>
      <address>
        <city>Batumi</city>
        <zip>6000</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resaerch Institte of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Neo Medi&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0131</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD &quot; High Technology Medical Center University Clinic&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef-Hospital -Universitätsklinik Ruhr-Universität Bochum, Leitende Ärztin der Abt. für Hämatologie und Onkologie, Medizinische Klinik I</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie -Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Wuppertal, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Baixo Vouga, E.P.E. (Hospital Infante D. Pedro), Oncologia Médica</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga, Oncologia Médica</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia do Porto, Francisco Gentil, E.P.E., Oncologia Médica</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology and Radiology of Serbia, Clinic for Medical Oncology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Gastroenterology department</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun, Insitute for Oncology</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac, Center for Oncology</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle sjukhus, Oncology unit</name>
      <address>
        <city>Gävle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska/Östra sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Sjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Portugal</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>stage IV</keyword>
  <keyword>FOLFOX6</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>PledOx</keyword>
  <keyword>Mangafodipir</keyword>
  <keyword>Febrile neutropenia</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>neutropenia</keyword>
  <keyword>neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Pyridoxal Phosphate</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 15, 2017</submitted>
    <returned>January 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

